Preclinical motor manifestations of Huntington disease
Andrew McGarry(Cooper Medical School of Rowan University), Kevin Biglan(Eli Lilly (United States))
Cited by 13
Related Papers
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
|Neurology|2016|137
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial
|The Lancet Neurology|2023|128
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
|The Lancet Neurology|2018|108
Pharmacologic approaches to the treatment of Huntington's disease
|Movement Disorders|2011|84